SCHEMBL23705291

SCHEMBL23705291

CO[C@@H]1O[C@H](COCc2ccccc2)[C@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1NC(C)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.53
MDM2 Q00987 2/20 0.53
SSTR1 P30872 1/20 0.52
SSTR2 P30874 1/20 0.52
SSTR4 P31391 1/20 0.52
SSTR3 P32745 1/20 0.52
SSTR5 P35346 1/20 0.52
MDM4 O15151 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
PTPN1 P18031 8/20 0.50
PTPN2 P17706 4/20 0.50
NT5E P21589 1/20 0.50
LMNA P02545 1/20 0.49
KMT2A Q03164 1/20 0.49
POLB P06746 1/20 0.48
CDC25B P30305 5/20 0.47
PTPN6 P29350 2/20 0.46
PTPN11 Q06124 2/20 0.46
TACR2 P21452 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153085 1.00 TP53 (0.53) TP53MDM2SSTR1SSTR2SSTR4
SCHEMBL7153092 1.00 TP53 (0.53) TP53MDM2SSTR1SSTR2SSTR4
SCHEMBL13491599 0.94 POLB (0.52) TP53MDM2SSTR1SSTR2SSTR4
SCHEMBL7583524 0.94 POLB (0.52) TP53MDM2SSTR1SSTR2SSTR4
SCHEMBL15514084 0.93 TP53 (0.55) TP53MDM2MDM4HSP90AA1HSP90AB1
SCHEMBL16967451 0.93 TP53 (0.55) TP53MDM2MDM4HSP90AA1HSP90AB1
SCHEMBL5840884 0.93 TP53 (0.55) TP53MDM2MDM4HSP90AA1HSP90AB1
SCHEMBL5840927 0.93 TP53 (0.55) TP53MDM2MDM4HSP90AA1HSP90AB1
SCHEMBL10525210 0.92 SSTR4 (0.51) TP53MDM2SSTR1SSTR2SSTR4
SCHEMBL11779626 0.91 SSTR1 (0.52) TP53MDM2SSTR1SSTR2SSTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
EP-4097138-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS Avila Therapeutics, Inc. (US) 2022-12-07 EP disclosed
CN-115066438-A ASGPR binding compounds for degrading extracellular proteins 阿维拉治疗公司 2022-09-16 CN disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2022035997-A1 IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS AVILAR THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2021155317-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A TP53 2592/4885MDM2 3794/4885SSTR1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.